RCM
MDGL icon

Rotella Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Rotella Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-717
Closed -$103K – 364
2014
Q2 		$103K Buy
717
+383
+115% +$56K 0.09% 218
2014
Q1 		$50K Buy
+334
New +$65.8K 0.06% 172

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Rotella Capital Management's MDGL Position: Q3 2014 in Review

Rotella Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2014, closing a stake of 717 shares — an estimated $103K sold.

Rotella Capital Management first reported a position in MDGL in Q1 2014 and held it in 2 quarters. The position peaked at $103K in Q2 2014. 92 funds tracked by Wall St. Rank hold MDGL as of Q3 2014.

  • Rotella Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Rotella Capital Management sold 717 Madrigal Pharmaceuticals shares in Q3 2014, an estimated $103K.
  • Rotella Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Rotella Capital Management's Madrigal Pharmaceuticals position peaked at $103K in Q2 2014.
  • 92 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2014.

Based on Rotella Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.